Journal
BLOOD COAGULATION & FIBRINOLYSIS
Volume 17, Issue 8, Pages 615-619Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MBC.0b013e3280100d1e
Keywords
bleeding; NovoSeven; recombinant activated factor VII; von Willebrand disease
Categories
Ask authors/readers for more resources
Recombinant activated factor Vil (NovoSeven), a novel hemostatic agent originally developed for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors, has been recently employed with benefit for the management of hemorrhages in other nonhemophilic congenital and acquired hemostatic abnormalities. This review focuses on the use of this drug in acquired and congenital von Willebrand disease. The analysis of the literature data shows that recombinant activated factor VII is an effective agent for the treatment of refractory bleeding in von Willebrand disease patients and for the treatment or prevention of bleeding in those patients with alloantibodies or autoantibodies against von Willebrand factor. Further studies are needed, however, to assess its safety and to optimize the dosages and regimens of therapy in such patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available